Article

VisiJet expects quick approval for corneal tissue tool

VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.

VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.

The company has secured worldwide distribution rights from Gebauer Medizintechnik GmbH of Neuhausen, Germany. The product has earned the CE mark and is being sold in Europe and Korea.

VisiJet expects an expedited FDA approval by fall.OT

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.